PrediSurge, Cardiovascular Digital Twin Company, Closes €6.5 Million Round

PrediSurge, a French company that develops predictive software solutions for vascular and cardiac disease interventions, has closed a €6.5 million Series A round (4 of which is equity). Leading the deal were Liftt, an Italian venture capital firm focused on deep-tech investments, and the European Innovation Council Fund (Eic Fund).

Saint Victor Capital, UI Investissement – Metropoles Innovations, and Crédit Agricole LHL Capital Innovation also participated in the financing. Part of the financial resources come from the EIC accelerator program in which Predisurge participated under Horizon Europe, the European Union’s research and innovation program that provides access to direct and grant funding.

Read more about PrediSurge and find the latest business news of the day with our companion app Born2Invest, available for free for both Android and iOS devices.

What PrediSurge does

Through the application of advanced “digital twin” technology, PrediSurge enables physicians and MedTech companies to refine intervention strategies and optimize medical device design. A system that, as of 2017, enables work on the “cardiovascular digital twin.”

“The one in Predisurge is an investment that respects our belief about the disruptive effect of digital twin technology in the healthcare sector,” commented Francesca Mongardi, Project Manager at LIFTT S.p.a.

“By enabling accurate simulations and customized treatment strategies, PrediSurge’s solutions have the potential to significantly improve the safety and efficiency of minimally invasive cardiovascular procedures. These patient-specific “digital twins” have the potential to transform cardiovascular interventions by providing medical professionals and MedTech companies with pre-operative support and prediction of post-operative complications.”

In recent years, in fact, PrediSurge has developed PlanOpTM, software that uses preoperative images to create numerical models that simulate the biomechanical behavior of arteries and valves by generating patient-specific “digital twins.”

PrediSurge goals

The financial resources will be used by the company in three crucial areas: to expand its international presence, extend its track record, and industrialize the PlanOpTM platform to enable easy scalability and global adoption of PrediSurge’s current and future products.

With the injection of new capital, PrediSurge aims to improve its existing products, expand its capabilities, and explore new segments in the vascular and structural heart fields.

__

(Featured image by jesse orrico via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in StartupItalia. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.